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Aspirin prevents resistin-induced endothelial
dysfunction by modulating AMPK, ROS, and
Akt/eNOS signaling
Hsiu-Chung Ou, PhD,a Wen-Jane Lee, PhD,b,c Ching-Mei Wu, MS,b Judy Fuh-Meei Chen, PhD,d and
Wayne Huey-Herng Sheu, MD, PhD,e,f,g,h Taichung and Taipei, Taiwan, Republic of China
Background: Resistin, an adipocytokine, plays a potential role in cardiovascular disease and may contribute to increased
atherosclerotic risk by modulating the activity of endothelial cells. A growing body of evidence suggests that aspirin is a
potent antioxidant. We investigated whether aspirin mitigates resistin-induced endothelial dysfunction via modulation of
reactive oxygen species (ROS) generation and explored the role that AMP-activated protein kinase (AMPK), a negative
regulator of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, plays in the suppressive effects of aspirin
on resistin-induced endothelial dysfunction.
Methods: Human umbilical vein endothelial cells (HUVECs) were pretreated with various doses of aspirin (10-500
g/mL) for 2 hours and then incubated with resistin (100 ng/mL) for an additional 48 hours. Fluorescence produced
by the oxidation of dihydroethidium (DHE) was used to quantify the production of superoxide in situ; superoxide
dismutase (SOD) and catalase activities were determined by an enzymatic assay; and protein levels of AMPK-mediated
downstream signaling were investigated by Western blot.
Results: Treatment of HUVECs with resistin for 48 hours resulted in a 2.9-fold increase in superoxide production;
however, pretreatment with aspirin resulted in a dose-dependent decrease in production of superoxide (10-500 g/mL;
n  3 experiments; all P < .05). Resistin also suppressed the activity of superoxide dismutase and catalase by nearly 50%;
that result, however, was not observed in HUVECs that had been pretreated with aspirin at a concentration of 500
g/mL. The membrane translocation assay showed that the levels of NADPH oxidase subunits p47phoxand Rac-1 in
membrane fractions of HUVECs were threefold to fourfold higher in cells that had been treated with resistin for 1 hour
than in untreated cells; however, pretreatment with aspirin markedly inhibited resistin-induced membrane assembly of
NADPH oxidase via modulating AMPK-suppressed PKC- activation. Application of AMPK1-specific siRNA resulted
in increased activation of PKC- and p47phox. In addition, resistin significantly decreased AMPK-mediated downstream
Akt/endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) signaling and induced the phosphorylation of p38
mitogen-activated protein kinases, which in turn activated NF-B-mediated inflammatory responses such as the release of
interleukin (IL)-6 and IL-8, the overexpression of adhesion molecules, and stimulation of monocytic THP-1 cell
attachment to HUVECs (2.5-fold vs control; n  3 experiments). Furthermore, resistin downregulated eNOS and
upregulated inducible NO synthase (iNOS) expression, thereby augmenting the formation of NO and protein
nitrosylation. Pretreatment with aspirin, however, exerted significant cytoprotective effects in a dose-dependent
manner (P < .05).
Conclusions: Our findings suggest a direct connection between adipocytokines and endothelial dysfunction and provide
further insight into the protective effects of aspirin in obese individuals with endothelial dysfunction. (J Vasc Surg 2012;
55:1104-15.)
Clinical Relevance: Resistin has been reported to involve in the inflammatory process, which is a common feature in
metabolic syndrome, insulin resistance status, and vascular diseases. This study underscores the potential clinical benefits
and application of aspirin in prevention of obese-associated vascular dysfunction.
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Volume 55, Number 4 Ou et al 1105Obese patients often present with dysregulation of
circulating adipocytokines, a condition that can lead to
endothelial dysfunction and vascular inflammation. Recent
studies suggest that increased plasma levels of resistin, a
circulating protein derived from adipocytes and mononu-
clear cells,1 correlate with determinants of metabolic syn-
drome in humans2 and are associated with increased sever-
ity of microangiopathy in patients with type 2 diabetes.3
Resistin has been shown to reduce endothelium-dependent
and endothelium-independent vasorelaxation and to de-
crease endothelial nitric oxide (NO) synthase (eNOS) ex-
pression in porcine coronary artery endothelial cells.4 In
cultured endothelial cells, resistin has been shown to up-
regulate the expression of vascular cell adhesion molecule-1
(VCAM-1) and monocyte chemoattractant protein-1
through NF-B signaling.5
Recently, Shen et al6 found that resistin inhibited
insulin-stimulated Akt and eNOS phosphorylation/activa-
tion and activity in endothelial cells. In addition, Chen et
al7 recently reported that resistin downregulated eNOS
through overproduction of superoxide radical anion and
activation of P-38 and JNK kinase. In that study, the
authors also showed that resistin decreased the antioxidant
activities of superoxide dismutase (SOD) and catalase,
which in turn impaired the internal cellular response to
oxidative stress in resistin-treated cells.
AMP-activated protein kinase (AMPK) is a heterotri-
meric enzyme consisting of a catalytic subunit () and two
regulatory subunits ( and ). AMPK influences a number
of signaling cascades that result in antiatherosclerotic ef-
fects, such as improved NO bioavailability, attenuated free-
radical generation, and the activation of angiogenic fac-
tors.8 There is evidence that AMPK plays important roles in
preventing endothelial dysfunction by upregulating the
Akt/eNOS/NO pathway9 and by suppressing the activa-
tion of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase in vascular tissues.10
Aspirin has been shown to inhibit inflammation and
reduce the onset of cardiovascular disease and certain can-
cers. Theoretically, the clinical administration of aspirin
should be effective at reducing vascular inflammation, es-
pecially in obese patients with high levels of circulating
adipocytokines. However, the beneficial effects of aspirin
on adipocytokine-induced endothelial cell dysfunction re-
main largely unstudied. Evidence from explorative clinical
trials suggests that treatment with low-dose aspirin can help
maintain vascular homoeostasis by improving endothelium-
dependent arterial relaxation.11 The underlying mecha-
nism may be the induction of NO release from vascular
endothelium.12 In addition, it has been reported that
aspirin inhibits PKC activation, an upstream regulator of
NADPH oxidase activation13 and eNOS inactivation,9 and
that chronic administration of aspirin leads to a decrease in
NADPH oxidase activity.14
We, therefore, examined whether aspirin exerts protec-
tive effects against resistin-induced endothelial cell dys-
function and, if so, whether AMPK, an upstream regulator If PKC-mediated NADPH oxidase activation and the Akt/
NOS/NO signaling pathway, is involved in the process.
ETHODS
Cell cultures. Human umbilical vein endothelial cells
HUVECs) were isolated from human umbilical cords with
ollagenase and were used at passage 2 to 3 as described
reviously.15 THP-1, a human monocytic leukemia cell
ine, was obtained from ATCC (Rockville, Md) and cul-
ured in RPMI with 10% fetal bovine serum at a density of
to 5  106 cells/mL as suggested in the product specifi-
ation sheet provided by the vendor.
Measurement of superoxide production. The effect
f aspirin on superoxide production in HUVECs was de-
ermined by a fluorometric assay using dihydroethidium
DHE; Sigma, St. Louis, Mo). HUVECs (104 cells/well)
ere seeded in 96-well plates, preincubated with various
oncentrations of aspirin for 2 hours, and then exposed to
esistin (100 ng/mL) for another 48 hours. Cells were then
xposed to 10-M DHE for 1 hour. Superoxide forma-
ion occurs largely through activation of NADPH oxi-
ase, but also through uncoupling of endothelial NO
ynthase, xanthine oxidase, peroxisomes, and through
irect superoxide release. In parallel experiments, diphe-
yleneiodonium (DPI), a potent inhibitor of flavin-
ontaining oxidases, was used to inhibit reactive oxygen
pecies (ROS) production mediated by various flavoen-
ymes, including NADPH oxidase, quinine oxidoreduc-
ase, cytochrome P450 reductase, and NO synthase. Fluo-
escence intensity was measured with a fluorescence
icroplate reader (Labsystems, Mountain View, Calif) cal-
brated for excitation at 530 nm and emission at 590 nm.
Measurement of antioxidant enzyme activity. To
etermine the effects of aspirin after resistin exposure, SOD
nd catalase activities in the homogenate were determined
y an enzymatic assay using a commercial kit (Calbiochem,
a Jolla, Calif) according to the manufacturer’s instruc-
ions. Enzyme activity was converted to units per milligram
f protein.
Immunoblotting. HUVECs were grown to conflu-
nce, pretreated with various concentrations of aspirin for
hours, and then stimulated with resistin (100 ng/mL)
or 48 hours. After treatment, cytosolic and membrane
rotein fractions as well as cytosolic and nuclear protein
ractions were extracted. Expression levels of p-Akt, Akt,
hospho-eNOS (p-eNOS), eNOS, p-P-38, P-38, IB-,
nducible NO synthase (iNOS), nitrotyrosine, phospho-
cetyl-CoA carboxylase (p-ACC), ACC, AMPK, and
-AMPK in cytosolic fractions and p47phox, Rac-1,
p91phox, p22phox, PKC- and NF-65bp in membrane
nd nuclear fractions were determined by SDS-PAGE and
mmunoblot assay.
Transfection with small interfering RNA (siRNA).
n-target Plus second manifestations of arterial disease trial
ool siRNAs for nontargeting control and AMPK1
ere purchased from Santa Cruz Biotechnology (Santa
ruz, Calif). Transient transfection was carried out usingNTERFERin siRNA transfection reagent (Polyplus Trans-
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April 20121106 Ou et alfection, New York, NY) according to the manufacturer’s
instructions. Two days after transfection, cells were treated
with reagent as indicated for further experiments.
Nitrite (NO2
) accumulation. NO2
 accumulation
was used as an indicator of NO production in the medium
and was assayed by Gries reagent.16 Briefly, 100L of Gries
reagent (1% sulfanilamide; 0.1% naphthylethylene diamine
dihydrochloride; 2.5% H3PO4; Sigma) was added to 100
L of each supernatant in triplicate wells of 96-well plates.
The plates were read using a microplate reader (Molecular
Devices, Palo Alto, Calif) at 550 nm against a standard
curve of NaNO2 in culture medium.
Total RNA isolation and real-time polymerase
chain reaction (PCR). In order to investigate the effects of
aspirin on resistin-induced inflammation and adhesion mole-
cule gene expression in endothelial cells, HUVECs were pre-
treated for 2 hours with indicated concentrations of aspirin
(10, 100, 300, and 500 g/mL) and then incubated with
resistin (100 ng/mL) for 48 hours. Total RNA was isolated
using TRIzol reagent. Oligonucleotides were designed using
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Fig 1. Effects of aspirin on resistin-induced reactive ox
umbilical vein endothelial cells (HUVECs) were pretreat
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incubated with the superoxide-sensitive fluorescent prob
cence images show the ROS level in control cells (left) and
of 500 g/mL aspirin (right). B, Fluorescence intensit
reader. Fluorescence distribution of DHE oxidation was
of superoxide dismutase (SOD) (C) and catalase (D) in H
indicated concentrations of aspirin were determined. D
analyses. #P 	 .05 vs untreated control; *P 	 .05 compathe software package Primer Express 2.0 (Applied Biosystems, woster City, Calif). The Ct value was defined as the number of
CR cycles in which the fluorescence signal exceeded the
etection threshold value. The relative amount of mRNA for
ach gene was normalized to that of the housekeeping gene
-actin.
Enzyme-linked immunosorbent assay. Interleukin
IL)-6, IL-8, intercellular adhesion molecule-1 (ICAM-1)-1,
CAM-1, and E-selectin concentrations in the cell culture
upernatants were determined using the Quantikine Human
mmunoassay kit (R&D Systems, Minneapolis, Minn).
riefly, HUVECs were cultured to confluence in 24-well
lates and pretreated for 2 hours with or without indicated
oncentrations of aspirin followed by incubation with resistin
100 ng/mL) for 48 hours. At the end of the treatment
eriod, 100-L aliquots of cell culture media were transferred
o anti-IL-6, IL-8, ICAM-1, VCAM-1, and E-selectin anti-
ody-coated wells and incubated for 2 hours. Peroxidase-
onjugated secondary polyclonal antibody was then added to
ach well. Following a wash to remove any unbound anti-
ody-enzyme reagents, a substrate solution was added to each
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Volume 55, Number 4 Ou et al 1107Color development was stopped and absorbance was mea-
sured at 450 nm using a microplate reader (Molecular De-
vices, Sunnyvale, Calif).
Adhesion assay. HUVECs at 1  105 cells/mL were
cultured in 96-well flat-bottom plates (0.1 mL/well) for 1 to
2 days. Cells were then pretreated with the indicated concen-
trations of aspirin for 2 hours followed by resistin (100 ng/
mL) for 48 hours. The medium was then removed and 0.1
mL/well of THP-1 cells (prelabeled with BECF-AM 4 M
for 30 minutes in RPMI at a cell density of 1 106 cell/mL)
was added to fresh RPMI. The cells were allowed to adhere at
37°C for 1 hour in a 5% CO2 incubator. The nonadherent
cells were removed by gentle aspiration. Plates were washed
three times with M199. The number of adherent cells was
estimated by microscopic examination and then the cells were
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Fig 3. Aspirin prevented resistin-induced PKC- translocation via AMP-activated protein kinase (AMPK) phosphorylation.
Humanumbilical veinendothelial cells (HUVECs)werepretreatedwithaspirin (10-500g/mL)ordiphenyleneiodonium(DPI;
5 M) or 5-aminoimidazole-4-carboxamide 1--D-ribofuranoside (AICAR) (500 M) for 2 hours followed by exposure to
resistin (100 ng/mL) for a further 1-hour period. Representative Western blots and summary data show that aspirin protected
against resistin-induced AMPK dephosphorylation (A and B) and PKC- translocation to the plasma membrane (C and D). In
AMPK knockdown experiments, HUVECs were transfected with AMPK1 siRNA for 24, 48, and 72 hours. Protein expression
of AMPK (E) and phosphorylated acetyl-CoA carboxylase (p-ACC) (F) were checked by Western blots. The effects of
aspirin on resistin-induced membrane translocation of PKC- and p47phox were abolished in cells that had been
transfected with AMPK siRNA for 48 hours (G-I). Preparation of membrane and cytosolic proteins is described in
the Materials and Methods section. The levels of cytosolic and membrane protein were normalized to the levels of
-actin and flotillin-1, respectively. The values represent means  SEM of three separate experiments. #P 	 .05 vs
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increase in superoxide; however, pretreatment with aspirin
(10-500 g/mL) significantly inhibited resistin-induced
superoxide in a dose-dependent manner (Fig 1,A and B; all
P 	 .05). In order to examine the mechanisms by which
aspirin exerts its antioxidant action in HUVECs exposed to
resistin, we analyzed the catalytic activity of SOD and
catalase by measuring the dismutation of superoxide to
H2O2 and the decomposition of H2O2 to water in
HUVECs that had been treated with 100 ng/mL of
resistin for 48 hours. As shown in Fig 1, C and D, resistin
led to a 50% reduction in SOD and catalase activity;
however, pretreatment with aspirin (10-500 g/mL)
significantly attenuated the resistin-induced suppression
of SOD and catalase activity in a dose-dependent manner
(all P 	 .05).
Aspirin attenuated resistin-induced membrane assem-
bly of NADPH oxidase complex. The membrane translo-
cation assay showed that the levels of p47phox and Rac-1 in
membrane fractions were threefold to fourfold higher in
HUVECs that had been treated with resistin for 1 hour
than in untreated cells (Fig 2, A-C). In addition, the
protein levels of gp91phox and p22phox were twofold to
threefold higher in HUVECs that had been exposed to
resistin for 48 hours. However, pretreatment of resistin-
exposed cells with various concentrations of aspirin or
5-M DPI (an inhibitor of flavin-containing oxidases) led
to a dose-dependent reduction both in membrane translo-
cation of p47phox and Rac-1 and in protein levels of
gp91phox and p22phox (10-500 g/mL; all P	 .05; Fig 2,
D-F).
Aspirin blocked the resistin-induced suppression of
AMPK phosphorylation. AMPK functions as a physiolog-
ical suppressor of NADPH oxidase.17 In addition, AMPK
activation has been shown to improve endothelial function
by counteracting oxidative stress in endothelial cells.18 We,
therefore, determined whether AMPK activation is in-
volved in the inhibitory effect of aspirin on NADPH oxi-
dase. As shown in Fig 3, A and B, treatment of HUVECs
with resistin (100 ng/mL) for 1 hour led to a reduction in
phosphorylated AMPK; however, aspirin or DPI blocked
the resistin-induced suppression of AMPK phosphoryla-
tion.
Aspirin suppressed the resistin-induced activation of
PKC-.  Previous studies have reported that AMPK
inhibits the activation of PKC19 and that PKC- is an
upstream mediator of NADPH oxidase.20 We, therefore,
explored whether the suppressive effects of aspirin on
NADPH oxidase are mediated through the PKC- signal-
ing pathway. As shown in Fig 3, C and D, after a 1-hour
exposure to resistin, there was a twofold increase in the
expression of PKC-; however, there was a marked dose-
dependent reduction in PKC- expression in HUVECs
that had been pretreated with aspirin (all P 	 .05). In
addition, resistin-induced PKC- activation was abolished
by adding the AMPK activator 5-aminoimidazole-4-car-
boxamide 1--D-ribofuranoside (AICAR), suggesting that fKC- is a target of aspirin downstream of AMPK activa-
ion.
AMPK knockdown impaired the inhibitory effects of as-
irin on resistin-induced PKC and p47phox activation. To
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L) for an additional 1-hour period. In a parallel experiment,
UVECs were transfected with AMPK siRNA for 48 hours
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NOS, phospho-Akt (p-Akt), and phospho-eNOS (p-eNOS) (A).
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April 20121110 Ou et aleffects of aspirin on PKC--mediated resistin-induced NA-
DPH oxidase activation, we silenced AMPK1 gene expres-
sion using siRNA. As shown in Fig 3, E, the level of AMPK1
protein expression was reduced by 70% 48 hours after trans-
fection with AMPK1 siRNA. In addition, Western blot
analysis of the level of phosphorylation of ACC at Ser-79, a
substrate for AMPK, was carried out to evaluate the effec-
tiveness of AMPK knockdown and application of the phar-
macologic inhibitor Compound C. Our results confirmed
that transfection with AMPK siRNA as well as treatment
with Compound C markedly impaired ACC phosphoryla-
tion (Fig 3, F). We then used siRNA approaches to explore
the role that AMPK plays in the suppressive effects of
aspirin on resistin-induced PKC and p47phox activation. As
shown in Fig 3, G-I, the inhibitory effects of aspirin on
resistin-induced membrane translocation of PKC- as well
as p47phox were abolished in HUVECs that had been
transfected with AMPK1 siRNA.
The protective effects of aspirin involve AMPK/
Akt/eNOS activation. To investigate whether AMPK/
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pecific activator of AMPK, reversed resistin-impaired Akt/
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ownstream of AMPK activation (Fig 4, A-C; all P	 .05).
Aspirin inhibited NF-B activation via modulation
f p38mitogen-activated protein kinases (p38MAPK).
F-B is a heterodimeric protein composed of different
ombinations of members of the Rel family of transcription
actors.21 It has been shown that ROS activates p38
APK, which leads to the activation and nuclear translo-
ation of NF-B and the subsequent regulation of proin-
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Volume 55, Number 4 Ou et al 1111whether the effects of aspirin are associated with the p38
MAPK-NF-B signaling pathway. Our data showed that
resistin had no effect on the levels of p38 MAPK expression
after 1 hour of exposure, but that it markedly increased the
levels of phosphorylated p38 MAPK. In parallel experi-
ments, HUVECs that had been pretreated with aspirin
showed a significant dose-dependent reduction in phos-
phorylated p38 MAPK (Fig 5, A and B).
Activation of NF-B requires the dissociation of the
inhibitory factor IB-. Upon dissociation, NF-B is rap-
idly translocated to the nucleus where it presents as a
p65/p50 heterodimer and binds directly to its cognate
DNA sequence. As shown in Fig 5, C and D, after exposure
to resistin, IB- was degraded, thereby causing nuclear
translocation of NF-65bp. In contrast, in cells pretreated
with various concentrations of aspirin or SB203580, a
specific inhibitor of p38 MAPK, NF-B activation was
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April 20121112 Ou et alpressed the resistin-induced increase in NO release and
nitrosylation of tyrosine residues. Furthermore, the level of
NO generated in response to resistin was markedly reduced
in HUVECs exposed to the selective iNOS inhibitor
1400W.
Aspirin inhibited the expression of adhesion molecules
and adhesion of monocytes. Next, we explored the effect of
aspirin on cytokine release and expression of adhesion
molecules, downstream inflammatory events associated
with NF-B activation in endothelial cells exposed to resis-
tin. Both mRNA and protein levels of IL-6, IL-8, ICAM-1,
VCAM-1, and E-selectin were significantly higher in
HUVECs that had been incubated for 48 hours with
resistin at 100 ng/mL than in untreated control cells;
however, pretreatment with aspirin significantly inhibited
these NF-B-mediated inflammatory responses in a dose-
dependent manner (Fig 7, A-D). To test the effect of
aspirin on monocyte adhesion to HUVECs, confluent
*
  ICAM-1        VCAM-1       E
     ICAM-1       VCAM-1      
)B()A(
(C)
(D)
R
el
at
iv
e 
m
R
N
A
/
-a
ct
in
 E
xp
re
ss
io
n
0
1
2
3
4
5
0
1
2
3
4
#
#
  *
 *   *  *
   *
 * *
   *
    *
P
ro
te
in
 E
xp
re
ss
io
n 
(F
ol
ds
 o
f I
nc
re
as
e)
R
el
at
iv
e 
m
R
N
A
/
-a
ct
in
 E
xp
re
ss
io
n
0
1
2
3
4
control 
resistin 100 ng/ml
resistin+aspirin 10 g/ml
resistin+aspirin 100 g/ml
resistin+aspirin 300 g/ml
resistin+aspirin 500 g/ml
 IL-6                 IL-8      
  #
 #
*
*
    *
    *
*
   *
   *
P
ro
te
in
 E
xp
re
ss
io
n 
(F
ol
ds
 o
f I
nc
re
as
e)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6  ##
   *
  *   *
 IL-6                 IL-8      
*
  *
    *
 #
#
  *
    *
 *
    *
    *
*
  *
 *
Fig 7. Effect of aspirin on resistin-induced mRNA an
molecules, and monocytic cells adherence. Human umb
hours with or without indicated concentrations of aspiri
ng/mL) incubation for 48 hours. mRNA levels of interle
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-
polymerase chain reaction (PCR). Protein levels of IL-6
were determined by enzyme-linked immunosorbent assa
1 hour before aspirin treatment and then incubated f
adhesiveness of monocytic leukemia cells (THP-1) to
Methods section. The values represent means SEM fro
*P 	 .05 compared with resistin treatment; &P 	 .05 vsmonolayers of HUVECs were pretreated with aspirin (500 tg/mL) for 2 hours and then stimulated with resistin (100
g/mL) for 48 hours, followed by incubation with THP-1
ells for 1 hour at 37°C. As shown in Fig 7, E and F, resistin
timulated the adherence of THP-1 cells to HUVECs;
owever, aspirin treatment inhibited the attachment of
hose adhesion molecules to HUVECs. Simultaneous
reatment of HUVECs with resistin plus aspirin and
harmacologic inhibitors, including AMPK inhibitor
Compound C), Akt inhibitor (LY291002), or eNOS
nhibitor (cavtratin) markedly abolished the inhibitory
ffects of aspirin on monocyte adherence. Furthermore,
he addition of a PKC inhibitor (GF109203), an iNOS
nhibitor (1400W), or an exogenous NO donor (SNP)
eversed the resistin-induced adherence of monocytes to
UVECs.
ISCUSSION
We found that aspirin inhibits resistin-induced endo-
tin  
ctin  
   *
*
  *
   *
control           resistin       resistin +aspirin 
TH
P
-1
 a
dh
er
en
ce
 (%
 o
f c
on
tro
l)
0
50
100
150
200
250
300
resistin (100 ng/ml)
aspirin (500 g/ml)
Co
mp
ou
nd
 C
 10
 M
LY
29
10
02
 10
 M
ca
vtr
ati
n 1
0 
M
#
&
   *
SN
P 
25
M
14
00
W
 10
 M
  *
GF
10
92
03
 1
M
*
*
&
&
(E) 
(F) 
otein expression of inflammatory cytokines, adhesion
vein endothelial cells (HUVECs) were pretreated for 2
, 100, 300, and 500 g/mL) followed by resistin (100
(IL)-6, IL-8 (A), and intercellular adhesion molecule-1
well as E-selectin (B) were determined by real-time
(C), and ICAM-1, VCAM-1, as well as E-selectin (D)
ISA). E and F, Cells were pretreated with each inhibitor
hours with resistin (100 ng/mL). Resistin-induced
ECs was measured as described in the Materials and
ree separate experiments. #P	 .05 vs untreated control;
tin 
 aspirin treatment.-selec
E-sele
  *
#
   *
 *
 #
   *
 
d pr
ilical
n (10
ukin
1) as
, IL-8
y (EL
or 48
HUV
m thhelial cell dysfunction by activating AMPK. Our results
a
e
A
a
s
i
t
s
s
t
D
A
s
r
c
b
Z
b
a
t
d
i
o
JOURNAL OF VASCULAR SURGERY
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AMPK, which led to PKC--mediated NADPH oxidase
activation and subsequent superoxide generation as well as
impaired Akt/eNOS/NO signaling. In addition, resistin
caused a reduction in NO bioavailability, which in turn
activated p38 MAPK-mediated NF-B activation and sub-
sequently activated NF-B-mediated downstream inflam-
matory responses, such as the release of cytokines and the
expression of adhesion molecules in human endothelial
cells. Aspirin ameliorated these detrimental effects
through modulating the AMPK-mediated signaling
pathway (Fig 8).
Cardiovascular diseases are multifactorial diseases, with
ROS generation serving as the key mediator in vascular
inflammation and atherogenesis. The major source of ROS
production in endothelial cells is NADPH oxidase-derived
superoxide.23 AMPK helps to maintain the nonathergenic
and noninflammatory phenotype of endothelial cells via
suppression of PKC-mediated NADPH oxidase activa-
tion.24 In addition, PKC also inhibits eNOS activity by
phosphorylating Thr-495 and dephosphorylating Ser-
1177.9 Thus, loss of AMPK activity might increase PKC-
mediated NADPH oxidase activation18 as well as inactivate
eNOS.9 Ceolotto et al24 reported that exposure of cultured
Fig 8. Summary and working hypothesis showing the s
responses in resistin-exposed cells treated with aspirin.
inhibition or blockade. Resistin has been reported to b
feature in metabolic syndrome, insulin resistance status
clinical benefits and application of aspirin in preventio
activated protein kinase; eNOS, endothelial nitric oxide s
kin; iNOS, inducible nitric oxide snythase; NADPH, nic
mitogen-activated protein kinase; ROS, reactive oxygen
adhesion molecule.human endothelial cells to high levels of glucose resulted in tn increase in NADPH oxidase-derived superoxide; how-
ver, they found that the effect could be attenuated by
MPK-activating agents such as rosiglitazone. In addition,
ctivation of AMPK has been shown to increase the expres-
ion of the antioxidant MnSOD, inhibit high glucose-
nduced intracellular and mitochondrial ROS produc-
ion,25 and suppress NADPH oxidase in neutrophils,26
uggesting that activated AMPK may suppress oxidative
tress. Our finding that resistin-suppressed AMPK activa-
ion was abolished in cells that had been pretreated with
PI indicates that ROS acts as a negative upregulator of
MPK (Fig 3, A and B).
The regulatory effects of resistin on AMPK activity are
till controversial. A number of studies have shown that
esistin impairs AMPK signaling in liver,27,28 skeletal mus-
le,27,29 and adipose tissue,27,30 indicating that AMPK may
e a key intermediate molecule in resistin action. However,
hang et al31 found that resistin induces insulin resistance
y both AMPK-dependent and AMPK-independent mech-
nisms in HepG2 cells. Accumulating evidence supports
hat AMPK negatively regulates PKC, which in turn affects
iverse signaling pathways. For example, palmitic acid-
nduced endothelial CRP expression involves PKC-driven
xidative stress through AMPK inhibition.19 We found
ng cascades involved in the attenuation of inflammatory
¡ indicates activation or induction, and ; indicates
lved in the inflammatory process, which is a common
vascular diseases. This study underscores the potential
obese-associated vascular dysfunction. AMPK, AMP-
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April 20121114 Ou et alPKC as well as on p47phox transmembrane activation were
diminished in cells that had been exposed to AMPK siRNA
(Fig 3). We therefore, conclude that PKC- is a target of
aspirin downstream of AMPK activation.
NF-B is involved in diverse signaling pathways, in-
cluding those associated with oxidative stress-mediated in-
flammatory response. The activation of NF-B involves the
phosphorylation and degradation of IB- and the nuclear
translocation of p65. P-38 AMPK has been reported to
phosphorylate IB- thereby leading to IB- degradation
in ubiquitin proteasome systems,32 and p38 MAPK has
been shown to phosphorylate nuclear kinase mitogen-
activated and stress-activated protein kinase 1, which in
turn phosphorylates the transcriptionally active subunit of
NF-B, p65.33 As seen in Fig 5, C and D, the p38 MAPK
inhibitor SB203580 abolished the resistin-induced activa-
tion of NF-B. These findings further demonstrate the
linkage among p38 MAPK, resistin, and the activation of
NF-B.
NO is produced by eNOS at concentrations in the
nanomolar range under normal physiological conditions.
At those concentrations, NO has been shown to have
anti-inflammatory and protective effects by inhibiting the
activation of NF-B via stabilizing the IB- protein and
mediating the nitrosylation of cys 62 on the p50 subunit.34
In contrast, iNOS produces NO at concentrations in the
micromolar range. At those concentrations, NO can lead to
activation of NF-B, which in turn leads to the upregula-
tion of several major proinflammatory mediators such as
cytokines and the adhesion molecules VCAM-1 and
ICAM-1. In the present study, we found that some of the
adverse effects of resistin, namely inhibition of Akt and
eNOS phosphorylation and activation of P38 and NF-B,
were abrogated by aspirin treatment. In addition, pretreat-
ment with Compound C, a selective AMPK inhibitor, or
cavtratin, a selective eNOS inhibitor, antagonized the effect
of aspirin on inhibition of monocyte adherence, whereas
SNP, an exogenous NO donor, and 1400W, a selective
iNOS inhibitor, partially reversed the resistin-induced ad-
herence of monocytes, suggesting that the protective effect
of aspirin is due, at least in part, to its ability to upregulate
the AMPK/Akt/eNOS/NO signaling pathway.
Umbilical veins are probably the most widely used
source of human endothelial cells because they are more
easily accessible than other vessels, they are free from patho-
logic process, and they are physiologically more relevant
than many established cell lines. Unlike veins carrying
oxygen-poor blood to the heart in adults, umbilical veins
transport oxygen-rich blood from the placenta to the fetal
body. Plasma concentration levels of resistin in healthy
individuals are around 15 to 25 ng/mL, while plasma
resistin levels in patients with diabetes are around 35 to 40
ng/mL.35 In a prospective preventative study, Kim et al36
showed that aspirin administered daily at a dose of 325 mg
was more beneficial at preventing recurrent colorectal ade-
nomas in patients with higher body mass index than in
normal-weight patients. These findings are in agreement
with our results and further suggest the possible protectiveole of aspirin against increased adipose-driven cytokines
mong obese patients. The concentration of aspirin used in
his study (500 g/mL or 2.8 mM) is also similar to that
sed in previous studies37,38 and is close to the physiolog-
cally effective dose (0.5-2.0 mM).39 In vivo, typical ther-
peutic levels of aspirin range from 0.1 to 2 mM,40 with
to 2 mM in serum being required to achieve an
nti-inflammatory effect.40 Our findings support the no-
ion that aspirin could be a beneficial therapeutic agent
n obese individuals with chronic vascular inflammation
nd high levels of circulating resistin.
In conclusion, we have provided evidence that resistin
nduces inflammatory responses in endothelial cells by en-
ancing PKC--mediated NADPH oxidase activation, pre-
umably through dephosphorylation of its upstream mole-
ule AMPK. The detrimental effects caused by resistin were
eversed by adding aspirin at physiologically effective doses.
ur findings suggest a direct connection between adipocy-
okines and endothelial dysfunction and provide further
nsight into the protective effects of aspirin in obese indi-
iduals.
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